Psychedelic Harm Reduction: An Introduction

Abstract

Classic psychedelics have shown promising effects in the treatment of certain mental health conditions. They are also used recreationally, in spiritual contexts, and for personal development. Although they are generally non-toxic and have little to no addictive potential, their use can nevertheless involve certain risks and complications. In some cases, these may include the occurrence of acute and post-acute psychological crises and, in some instances, the development of psychiatric conditions requiring treatment. Due to the highly suggestible state induced by psychedelics, interpersonal risks may also play an important role.

The talk will provide an overview of the risks and adverse effects associated with classic psychedelics from a harm reduction perspective. Some ethical considerations will also be addressed. A classification of psychedelic-related disorders will be proposed and illustrated with case examples from clinical practice.

Biography

Psychiatrist and psychotherapist at the Psychiatric University Hospital of Charité at St. Hedwig Hospital in Berlin. Co-Head of the Psychedelic Substances Research Group at Charité. Head of a department of general psychiatry, an outpatient clinic for dual diagnosis and the „Ambulanz Psychedelische Substanzen“, an outpatient clinic treating patients with psychedelic-related disorders. Researcher and study therapist in trials investigating psychedelic assisted therapy. Editor of the volume Psychedelic Harm Reduction. Lecturer at the Berlin Institute for Psychotherapy and Psychoanalysis.